Anti-TB efficacy of PBTZ169 in mice with different genetic susceptibility to infection

B. Nikonenko (Moscow, Russian Federation), V. Makarov (Moscow, Russian Federation), I. Bocharova (Moscow, Russian Federation), M. Korotetskaya (Moscow, Russian Federation), E. Kondratieva (Moscow, Russian Federation), N. Sterzhanova (Moscow, Russian Federation), A. Apt (Moscow, Russian Federation)

Source: Virtual Congress 2020 – Non-tuberculous mycobacteria and latent tuberculosis infection
Session: Non-tuberculous mycobacteria and latent tuberculosis infection
Session type: E-poster session
Number: 2805
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. Nikonenko (Moscow, Russian Federation), V. Makarov (Moscow, Russian Federation), I. Bocharova (Moscow, Russian Federation), M. Korotetskaya (Moscow, Russian Federation), E. Kondratieva (Moscow, Russian Federation), N. Sterzhanova (Moscow, Russian Federation), A. Apt (Moscow, Russian Federation). Anti-TB efficacy of PBTZ169 in mice with different genetic susceptibility to infection. 2805

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy of anti-tuberculosis therapy with INH, RIF and Bedaquiline in mice with different genetic susceptibility to the infection
Source: International Congress 2019 – Tuberculosis: from basic science to patient care
Year: 2019

The efficacy of treatment of patients with drug resistant tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 661s
Year: 2007

The peculiarities of drug susceptibility of M. tuberculosis isolated from patients with late-stage HIV infection
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019

The prevalence of drug resistance tuberculosis in previously treated patients
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis
Year: 2008

Association of genetic markers with clinical course of patients with pulmonary tuberculosis with drug resistance
Source: Eur Respir J 2007; 30: Suppl. 51, 203s
Year: 2007

Evaluation the drug susceptibility testing and the prevalence of resistance to antituberculosis drugs in a chronic department
Source: Eur Respir J 2003; 22: Suppl. 45, 520s
Year: 2003

Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007


Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country.
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020


Role of HLA in genetic susceptibility to latent adenoviral infection and decreased lung function
Source: Eur Respir J 2005; 26: Suppl. 49, 250s
Year: 2005

Genetic polymorphism and phenotypic resistance of Mycobacterium tuberculosis to fluoroquinolones of different generations
Source: Virtual Congress 2021 – Advances in the diagnosis of tuberculosis, multidrug-resistant tuberculosis and nontuberculous mycobacterial disease
Year: 2021



Antimicrobial resistance genotype trends and association with host clinical characteristics in respiratory isolates of haemophilus influenzae
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011

Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children
Source: Eur Respir J 2004; 24: Suppl. 48, 648s
Year: 2004

Pharmacokinetics and drug susceptibility testing imply limited activity of current regimens for Mycobacterium avium complex disease
Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings
Year: 2012

Induction of M. tuberculosis (MTB) drug resistance (DR) mutations in HIV-infected hosts and pathways of further spread of the evolutionary successful drug-resistant MTB clonal lines
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020


The first experience of therapeutic dendritic cells vaccine administration in patients with extensively drug resistant lung tuberculosis
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018



Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs
Source: Annual Congress 2010 - Prognosis of tuberculosis
Year: 2010

Rapid diagnosis of bacterial co-infection and antimicrobial resistance in patients with SARS-Cov-2 infection
Source: Virtual Congress 2021 – Acute COVID - 19
Year: 2021



The effect of clarithromycin on immunity of mice with chronic respiratory infection caused by P. aeruginosa
Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi
Year: 2008


In vitro susceptibility testing and totally drug-resistant tuberculosis
Source: Eur Respir J 2013; 42: 291-292
Year: 2013